Blog
RSS FeedPosted by Michael Wonder on 06 May 2021
Medicines Australia updated position on intellectual property (in light of TRIPS waiver)
6 May 2021 - Medicines Australia continues to express our sympathies to all those affected by the pandemic. The importance ...
Posted by Michael Wonder on 06 May 2021
Australia has backed a global push to fast-track generic COVID-19 jabs
6 May 2021 - The Morrison government has joined an international push to fast-track the production of generic COVID-19 jabs, ...
Posted by Michael Wonder on 29 Oct 2020
European Patent Office rules in favour of Sanofi and Regeneron concerning Praluent (alirocumab)
29 October 2020 - Ruling invalidates Amgen’s European patent claims directed to PCSK9 antibodies relevant to Praluent (alirocumab). ...
Posted by Michael Wonder on 11 Oct 2020
Moderna vows to not enforce COVID-19 vaccine patents during pandemic
8 October 2020 - The company is also willing to license the technology behind its experimental coronavirus vaccine. ...
Posted by Michael Wonder on 08 Oct 2020
AstraZeneca vaccine document shows limit of no-profit pledge
8 October 2020 - Company has right under contract to declare pandemic over by July 2021. ...
Posted by Michael Wonder on 16 Aug 2020
Direct or indirect comparison: reliance on innovative drug data key to engaging data protection
15 August 2020 - The Federal Court recently issued its decision in Natco v Canada (Minister of Health), 2020 FC 788, ...
Posted by Michael Wonder on 29 Jul 2020
Moderna’s mysterious coronavirus vaccine delivery system
29 July 2020 - For a decade, Moderna has been working to develop mRNA technology that could turn the body’s cells ...
Posted by Michael Wonder on 21 Apr 2020
Coronavirus puts big pharma’s IP regime to the test
21 April 2020 - “Chaotic” is how Jorge Contreras, a law professor at the University of Utah, describes a struggle ...
Posted by Michael Wonder on 04 Mar 2020
Expanding access and reducing prices for drugs to prevent HIV. Should Government enforce its patent rights against the pharmaceutical industry?
3 March 2020 - On November 6, 2019, the Department of Health and Human Services (HHS) filed a lawsuit against Gilead ...
Posted by Michael Wonder on 24 Sep 2019
Institutional investors urging Congress to vote down CUSMA, citing effect on drug prices
23 September 2019 - A group of institutional investors representing more than US$500 billion is calling on the U.S. Congress ...
Posted by Michael Wonder on 12 Sep 2019
Big Pharma is abusing patents, and it's hurting Americans
12 September 2019 - The American patent system has, since our nation's founding, served as a cornerstone of innovation. But ...
Posted by Michael Wonder on 09 Sep 2019
Subscription model for antibiotic development
6 September 2019 - An unlikely answer to the global crisis in antibiotic resistance. ...
Posted by Michael Wonder on 22 Aug 2019
Gilead files challenge to government patents for HIV prevention pill
21 August 2019 - Gilead Sciences took the unusual step of mounting a challenge to U.S. government patents on Wednesday, ...
Posted by Michael Wonder on 21 Aug 2019
Chinese stealing health and medical research data: report
21 August 2019 - The global healthcare sector, including Australia, faces increasing cyber threats and malicious activity from Chinese groups, ...
Posted by Michael Wonder on 30 Jul 2019
Is ‘competitive licensing’ proposed in HR 1046 practical for lowering drug prices?
29 July 2019 - The pricing of prescription drugs is a source of current public consternation in the US. ...